Breaking News

WuXi Biologics to Build CRDMO Center in Singapore

Investment will include a R&D service center and large-scale drug substance and drug product manufacturing facilities for biologics.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Biologics, a contract research, development and manufacturing organization (CRDMO), unveiled a 10-year $1.4 billion investment plan to expand the company’s research, development and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L biomanufacturing capacity to WuXi Biologics’ global network by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete. Followin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters